HBW Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Homeopathic Dissolvable Strip Firm Shut Down By FTC Will Relaunch After Settling

This article was originally published in The Rose Sheet

Executive Summary

"It's pretty agonizing now. Our plan is to settle with them as fast as possible and move forward," says Jason Cardiff of Redwood Scientific Technologies in Upland, Calif. FTC alleges firm made unsubstantiated claims for dissolvable film strips for smoking cessation, weight loss and sexual performance; billed customers for unauthorized sales; made "abusive telemarketing through robocalls"; and stated false earnings claims to attract multilevel marketing distributors.

You may also be interested in...



US Dissolvable Film Supplement Firm Won’t Lift Curtain On Sequel After Court Bans DTC Sales

California federal court approves FTC summary judgement motion against Redwood Scientific Technologies, its owners and other companies they formed to market what they promoted as homeopathic products using oral film delivery format.

OTC Homeopathy Group Revises Label Disclaimers In Light Of FTC Scrutiny

American Association of Homeopathic Pharmacists says its new recommended disclaimer for product labels – saying claims are not based on accepted medical evidence – is supported by research showing the language is clear to consumers. 

Deal Watch: Taking Care Of Business Before J.P. Morgan

Under Momenta/CSL autoimmune partnership, Momenta can opt in to co-development or commercialization on recombinant Fc receptor modulator or just earn a revenue stream from CSL’s efforts with the preclinical candidate. Pieris and Servier sign broad-based immuno-oncology collaboration, while Arena hands off the disappointing Belviq to Eisai.

Related Content

Topics

Latest News
UsernamePublicRestriction

Register

RS122391

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel